Quick Answer
Sana Biotechnology, Inc. reported Cash and Equivalents of $71.87 million for fiscal year 2025.
Sana Biotechnology, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $71.87M | -43.7% |
| 2024 | $127.57M | -4.5% |
| 2023 | $133.52M | -24.5% |
| 2022 | $176.76M | -30.1% |
| 2021 | $253.03M | +102.7% |
| 2020 | $124.81M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $103.36M | -18.6% | +45.0% |
| June 30, 2025 | $71.27M | -47.2% | -25.9% |
| March 31, 2025 | $96.13M | -45.7% | -24.6% |
| December 31, 2024 | $127.57M | -4.5% | +0.4% |
| September 30, 2024 | $127.00M | -24.6% | -5.9% |
| June 30, 2024 | $134.96M | -22.3% | -23.8% |
| March 31, 2024 | $177.05M | +10.3% | +32.6% |
| December 31, 2023 | $133.52M | -24.5% | -20.7% |
- Sana Biotechnology, Inc. showed a decrease of -43.7% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2020–2025 period, Sana Biotechnology, Inc.’s cash and equivalents has declined by 42.4% (from $124.81 million to $71.87 million).
- The most recent figure is from Sana Biotechnology, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 3, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: